NervGen Pharma Corp. announced its Board of Directors has unanimously appointed Adam Rogers, MD, Age 56, as President, effective immediately on February 9, 2026. Dr. Rogers will continue leading the Company?s growth and execution of its mission to transform the lives of individuals living with spinal cord injury.
Adam Rogers, MD, has served on NervGen?s Board of Directors since July 2022 and was appointed Chairman and Interim Chief Executive Officer in July 2025 as part of a leadership transition supporting the Company?s next stage of growth. Dr. Rogers is a Principal of Boston-based PFP Biosciences Holdings and a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous. Dr. Rogers previously co-founded Hemera Biosciences, a clinical-stage biotechnology company developing a one-time investigational gene therapy administered as an outpatient intravitreal injection to preserve vision in patients with geographic atrophy.
Dr. Rogers served as Chief Executive Officer from 2017 until December 2020, when the rights to its lead program were acquired by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Earlier in his career, Dr. Rogers served as an Assistant Professor of Ophthalmology at the New England Eye Center of Tufts Medical Center. He has authored numerous peer-reviewed publications and holds an M.D. from Emory University School of Medicine.
